FY2029 EPS Estimates for NeuroPace Raised by Leerink Partnrs

Key Points

• Leerink Partners raised their FY2029 earnings per share (EPS) estimate for NeuroPace from $0.46 to $0.57, while the consensus estimate for the company’s full-year earnings remains at ($1.00) per share.
• NeuroPace reported a quarterly EPS of (0.26), falling short of the consensus estimate and having a revenue of $23.52 million, which surpassed expectations.
• The stock has a consensus rating of Buy with a target price averaging around $16.60, indicating positive sentiment among multiple analysts.

NeuroPace, Inc. (NASDAQ:NPCE - Free Report) - Research analysts at Leerink Partnrs raised their FY2029 EPS estimates for NeuroPace in a report released on Tuesday, August 12th. Leerink Partnrs analyst M. Kratky now expects that the company will post earnings per share of $0.57 for the year, up from their previous forecast of $0.46. The consensus estimate for NeuroPace's current full-year earnings is ($1.00) per share.

NPCE has been the topic of several other reports. HC Wainwright started coverage on shares of NeuroPace in a research note on Wednesday, May 28th. They issued a "buy" rating and a $18.00 price target on the stock. Cantor Fitzgerald reiterated an "overweight" rating and issued a $17.00 price target on shares of NeuroPace in a research note on Wednesday, May 14th. Zacks Research lowered shares of NeuroPace from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, August 13th. Wells Fargo & Company dropped their price target on shares of NeuroPace from $17.00 to $15.00 and set an "overweight" rating on the stock in a research note on Wednesday, August 13th. Finally, JPMorgan Chase & Co. increased their price target on shares of NeuroPace from $14.00 to $16.00 and gave the company an "overweight" rating in a research note on Wednesday, May 14th. Five investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $16.60.

NeuroPace Stock Down 0.3%

NASDAQ:NPCE traded down $0.0240 during mid-day trading on Thursday, hitting $8.3960. The stock had a trading volume of 93,590 shares, compared to its average volume of 274,933. The company has a market capitalization of $277.74 million, a PE ratio of -9.97 and a beta of 1.89. NeuroPace has a twelve month low of $5.45 and a twelve month high of $18.98. The company has a current ratio of 5.47, a quick ratio of 4.51 and a debt-to-equity ratio of 3.02. The stock has a 50-day simple moving average of $9.82 and a two-hundred day simple moving average of $11.66.

NeuroPace (NASDAQ:NPCE - Get Free Report) last issued its earnings results on Tuesday, August 12th. The company reported ($0.26) earnings per share for the quarter, missing the consensus estimate of ($0.24) by ($0.02). The firm had revenue of $23.52 million during the quarter, compared to analyst estimates of $23.08 million. NeuroPace had a negative net margin of 29.29% and a negative return on equity of 168.61%. NeuroPace has set its FY 2025 guidance at EPS.

Hedge Funds Weigh In On NeuroPace

A number of hedge funds have recently modified their holdings of the business. Lazard Asset Management LLC grew its position in shares of NeuroPace by 2,445.5% during the second quarter. Lazard Asset Management LLC now owns 78,885 shares of the company's stock worth $878,000 after acquiring an additional 75,786 shares during the last quarter. Engineers Gate Manager LP grew its position in shares of NeuroPace by 33.6% during the second quarter. Engineers Gate Manager LP now owns 13,609 shares of the company's stock worth $152,000 after acquiring an additional 3,420 shares during the last quarter. PDT Partners LLC purchased a new position in NeuroPace in the 2nd quarter valued at $264,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in NeuroPace by 60.7% in the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 13,160 shares of the company's stock valued at $147,000 after buying an additional 4,972 shares during the last quarter. Finally, Qube Research & Technologies Ltd grew its position in NeuroPace by 74.7% in the 2nd quarter. Qube Research & Technologies Ltd now owns 112,637 shares of the company's stock valued at $1,255,000 after buying an additional 48,175 shares during the last quarter. 78.83% of the stock is currently owned by hedge funds and other institutional investors.

About NeuroPace

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.